IFNA2 and melanoma: Regarding the clinical benefit of IFN-α in the adjuvant therapy of high-risk resected melanoma patients, this is a subject of debate: several results indicate improved overall and recurrence-free survival [70], while others report low or no effect on overall survival [71].